<SEC-DOCUMENT>0001104659-26-032427.txt : 20260320
<SEC-HEADER>0001104659-26-032427.hdr.sgml : 20260320
<ACCEPTANCE-DATETIME>20260320072507
ACCESSION NUMBER:		0001104659-26-032427
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260320
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260320
DATE AS OF CHANGE:		20260320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Milestone Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001408443
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38899
		FILM NUMBER:		26776088

	BUSINESS ADDRESS:	
		STREET 1:		1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H4M 2X6
		BUSINESS PHONE:		(514) 336-0444

	MAIL ADDRESS:	
		STREET 1:		1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H4M 2X6
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm269403d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:mist="http://milestonepharma.com/20260320">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_mist_milestonepharma.com_20260320 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20260320_20260320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001408443 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000004" name="dei:EntityCentralIndexKey">0001408443</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-20" id="xdx2ixbrl0012" name="dei:EntityIncorporationStateCountryCode">A8</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-20" id="xdx2ixbrl0014" name="dei:EntityTaxIdentificationNumber">00-0000000</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-20" id="xdx2ixbrl0018" name="dei:EntityAddressStateOrProvince">QC</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mist-20260320.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001408443</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-20</xbrli:startDate>
        <xbrli:endDate>2026-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20260320__20260320_z1PmaJOH54q6"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the<br/>
Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--DocumentPeriodEndDate_c20260320__20260320_zYg8FHu79Nke"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 20, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_901_edei--EntityRegistrantName_c20260320__20260320_zI3dkcF7bTl7"><b><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000011" name="dei:EntityRegistrantName">MILESTONE
PHARMACEUTICALS INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 32%; text-align: center"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_dxL_c20260320__20260320_zmo4Azx9CDvh" title="::XDX::A8"><span style="-sec-ix-hidden: xdx2ixbrl0012">Qu&#233;bec</span></span></td>
    <td style="font-weight: bold; width: 2%">&#160;</td>
    <td style="font-weight: bold; width: 32%; text-align: center"><span id="xdx_90C_edei--EntityFileNumber_c20260320__20260320_zKeTZ3h3G29d"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000013" name="dei:EntityFileNumber">001-38899</ix:nonNumeric></span></td>
    <td style="font-weight: bold; width: 2%">&#160;</td>
    <td style="font-weight: bold; width: 32%; text-align: center"><span id="xdx_901_edei--EntityTaxIdentificationNumber_dxL_c20260320__20260320_zN8K9ISlMRne" title="::XDX::00-0000000"><span style="-sec-ix-hidden: xdx2ixbrl0014">Not
    applicable</span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">(state or other jurisdiction of incorporation)</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">(I.R.S. Employer Identification No.)</td></tr>
</table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; width: 66%"><span id="xdx_908_edei--EntityAddressAddressLine1_c20260320__20260320_z5HkcvAbJ4lb"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000015" name="dei:EntityAddressAddressLine1">1111
    Dr. Frederik-Philips Boulevard</ix:nonNumeric></span>,</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 32%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span id="xdx_906_edei--EntityAddressAddressLine2_c20260320__20260320_zKcCoGBTV6Ak"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
    420</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span id="xdx_903_edei--EntityAddressCityOrTown_c20260320__20260320_z3THxCFlYRFc"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000017" name="dei:EntityAddressCityOrTown">Montr&#233;al</ix:nonNumeric></span>,
    <span id="xdx_900_edei--EntityAddressStateOrProvince_dxL_c20260320__20260320_zK4k3ptBG7k3" title="::XDX::QC"><span style="-sec-ix-hidden: xdx2ixbrl0018">Qu&#233;bec</span></span> <span id="xdx_90B_edei--EntityAddressCountry_c20260320__20260320_zYRjp6FrcWYf"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000019" name="dei:EntityAddressCountry">CA</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: center"><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20260320__20260320_zChL3On8KvAa"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000020" name="dei:EntityAddressPostalZipCode">H4M
    2X6</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area
code: <b>(<span id="xdx_908_edei--CityAreaCode_c20260320__20260320_zhGBIbJX1iv1"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000021" name="dei:CityAreaCode">514</ix:nonNumeric></span></b><b>)
<span id="xdx_90D_edei--LocalPhoneNumber_c20260320__20260320_zMnHvRqEHQb2"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000022" name="dei:LocalPhoneNumber">336-0444</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">(Former
name or former address, if changed since last report.)</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in"><span id="xdx_901_edei--WrittenCommunications_c20260320__20260320_zHhEYM9tsED3" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in"><span id="xdx_900_edei--SolicitingMaterial_c20260320__20260320_z3BA5uDXGOB6" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in"><span id="xdx_908_edei--PreCommencementTenderOffer_c20260320__20260320_z4FKKyU9W89k" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20260320__20260320_z31490C01iNf" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.9pt; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 38%; font-weight: bold; text-align: center">Title of each class</td>
    <td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 20%; font-weight: bold; text-align: center">Trading Symbol(s)</td>
    <td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 38%; font-weight: bold; text-align: center">Name of each exchange on which<br/>
    registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span id="xdx_903_edei--Security12bTitle_c20260320__20260320_zXuL9ZSsf27c"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000027" name="dei:Security12bTitle">Common
    Shares</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_edei--TradingSymbol_c20260320__20260320_zcf3aSSn9OZa"><ix:nonNumeric contextRef="AsOf2026-03-20" id="Fact000028" name="dei:TradingSymbol">MIST</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20260320__20260320_zMopgZckgVW9"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405
of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">Emerging growth company
<span id="xdx_903_edei--EntityEmergingGrowthCompany_c20260320__20260320_zShiOYAc5sp4" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-20" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02.</b></span></td>
    <td style="font-size: 10pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&#160;20, 2026, Milestone Pharmaceuticals
Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended
December&#160;31, 2025, which also provided an update on the commercial launch of CARDAMYST&#8482; (etripamil) Nasal Spray for the Treatment
of PSVT. A copy of the press release is furnished as Exhibit&#160;99.1 hereto and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information provided in this Item 2.02, including
Exhibit&#160;99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font-size: 10pt; text-align: justify; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm269403d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm269403d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated March&#160;20, 2026.</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File--the cover page&#160;XBRL tags are embedded within the Inline XBRL document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MILESTONE PHARMACEUTICALS INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Amit Hasija</span></td>
    <td style="width: 50%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amit Hasija</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March&#160;20, 2026</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6La4r7maXjiniFBki3lYXpbg1I60/eyTf0rohhkASzvlyhJiIJS1MgwzHeVXCHtuu0R6hwgsy2jMGR75aZxBmhVfjPGvrh/MH5hQYDEw6VeoUhMH6MA7rDGQaJzJWs7BkUsFuI6KvnpO9mBqtN7oBbWvYMXVs0Gvuxw97/SJLbT9EHZCdIZtBMpWj/AYlEwVbeugn8c1BWeYimgwViSXTvQuu4uXRfkkoGmxDnBvpf0cfArxKhg== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm269403d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><IMG SRC="tm269403d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B>Milestone Pharmaceuticals
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST&trade; (etripamil)
Nasal Spray for the Treatment of PSVT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>FDA approval of CARDAMYST represents first new option
in 30 years for the more than two million patients with PSVT</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Participants using CARDAMYST in clinical studies were
2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>CARDAMYST launch execution on track with positive initial
engagement in the product from healthcare providers and payers</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>$200 million pro
                                            forma cash supports strong launch and operating runway into late 2027; includes $106 million
                                            of cash at year-end and net proceeds from subsequent financing activities<SUP>1</SUP></I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Company to host investor call and webcast at 8:30am ET
today</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MONTREAL&nbsp;and&nbsp;CHARLOTTE, N.C.,&nbsp;March&nbsp;20,
2026 (GLOBE NEWSWIRE) --&nbsp;Milestone<SUP>&reg;</SUP> Pharmaceuticals Inc.&nbsp;(Nasdaq: MIST), a biopharmaceutical company focused
on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter
and full year ending&nbsp;December&nbsp;31, 2025, and provided corporate and regulatory updates. The main drivers of the fourth quarter
and full year 2025 activities include the U.S. Food and Drug Administration (FDA) approval of CARDAMYST&trade; <FONT STYLE="background-color: #FEFEFE">(etripamil)
nasal spray</FONT> for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm
in adults and product launch during this transformational year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are excited to see that our commercial
launch of CARDAMYST and the initial engagement with providers, patients and payers is tracking or exceeding our pre-launch expectations,&rdquo;
said&nbsp;Joseph Oliveto, President and Chief Executive Officer of&nbsp;Milestone Pharmaceuticals. &ldquo;Our national sales force was
fully deployed within eight weeks of our mid-December&nbsp;approval. Feedback from prescribers supports our belief that there is meaningful
demand for a convenient, self-administered option to treat episodes of PSVT, and patient reactions to having CARDAMYST in hand is inspiring.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="background-color: #FEFEFE"><B><I><U>Launch
Progress for CARDAMYST</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>CARDAMYST
                                            nasal spray was approved by the FDA on December&nbsp;12, 2025.</B> The FDA approval marks
                                            the first time that more than two million Americans with PSVT have a rapid-acting treatment
                                            option they can self-administer outside the emergency department or other healthcare setting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B><U>CARDAMYST
                                            became broadly available through retail pharmacies</U> in the United States in late January&nbsp;2026.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>National
                                            sales force deployed with promotional launch initiated in mid-February. </B>The sales force,
                                            consisting of approximately 60 sales representatives, is engaging primarily with cardiologists,
                                            electrophysiologists and advanced practice providers in the office-based setting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>Initial
                                            prescription status.</B> Early prescription fills support underlying demand and the effectiveness
                                            of our investments in reimbursement support ahead of coverage by payers. Most of the prescriptions
                                            filled to date are new patient starts and have been written by providers who are targeted
                                            by our sales force. As we accumulate a critical mass of data, future quarterly announcements
                                            are expected to report figures on prescriptions and prescribers, including total prescriptions,
                                            unique prescribers and new patient starts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>Marketing
                                            authorization application (MAA) for etripamil nasal spray in PSVT accepted by the European
                                            Medicines Agency (EMA). </B>The MAA incorporates the global clinical data package that supported
                                            the&nbsp;FDA&nbsp;approval of etripamil for the treatment of PSVT. A European decision on
                                            approval is expected by the first half of 2027. TACHYMIST&trade; is the conditionally approved
                                            brand name for etripamil nasal spray in&nbsp;Europe.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="background-color: #FEFEFE"><B><I><U>Presentation
of CARDAMYST at the American College of Cardiology (ACC) Scientific </U></I></B></FONT><B><I><U>Session</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>A
                                            poster &ldquo;<U>Minimal Blood Pressure Effects of Intranasal Etripamil for PSVT</U>&rdquo;
                                            will be presented at the ACC Annual Scientific Session, March&nbsp;30, in New Orleans. </B>The
                                            poster summarizes analysis of mean heart rate and blood pressure changes measured during
                                            clinical trials of CARDAMYST. The results demonstrate minimal blood pressure reduction during
                                            test dose and rare symptoms of hypotension or syncope, supporting the potential safe, self-administration
                                            of CARDAMYST for PSVT treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: #FEFEFE"><B>ACC
                                            Scientific Session to serve as a major launch event for the cardiology community.</B> The
                                            meeting will provide an opportunity to highlight CARDAMYST&rsquo;s clinical profile and engage
                                            prescribing physicians as commercial activities accelerate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B><I><U>E<FONT STYLE="background-color: #FEFEFE">tripamil
for Patients with Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)</FONT></U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Phase
                                            3 program in AFib-RVR planned. </B>The Company has developed a Phase 3 registrational program
                                            (incorporating the FDA&rsquo;s guidance) to evaluate self-administered etripamil as a potential
                                            treatment for patients with AFib-RVR. The Company intends to follow the supplemental New
                                            Drug Application (sNDA) regulatory approval pathway and expects to leverage the initial PSVT
                                            indication along with the results from the planned single Phase 3 study.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><I><U>Subsequent Financing Activities</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>$75
                                            million payment received under the Purchase and Sale Agreement (as amended, the Royalty Purchase
                                            Agreement) with RTW. </B>Milestone received a $75 million payment from RTW Royalty I DAC,
                                            an affiliate of RTW Investments, LP (RTW), on January&nbsp;12, 2026, in connection with the
                                            FDA approval of CARDAMYST. Milestone and RTW entered into the Royalty Purchase Agreement
                                            in 2023 (amended in July&nbsp;2025) providing RTW with the right to receive tiered quarterly
                                            royalty payments, or &ldquo;royalty interest,&rdquo; on the annual net product sales of CARDAMYST
                                            in the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>$19
                                            million in net proceeds from ATM sales and Series&nbsp;A Warrant exercises. </B>Milestone
                                            sold 5,526,590 shares through the Open Market Sale Agreement<SUP>SM</SUP> with Jeffries LLC
                                            for net proceeds of $10.9 million, after deducting sales agent commissions payable by the
                                            Company of $0.3 million. In addition, 5,666,666 Series&nbsp;A Warrants were exercised for
                                            net proceeds of $8.0 million, after deducting underwriting commissions payable by the Company
                                            of $0.5 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><I><U>Corporate Updates</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>David
                                            Sandoval appointed as General Counsel and Chief Compliance Officer.</B> Milestone announced
                                            the appointment of David Sandoval as General Counsel and Chief Compliance Officer on February&nbsp;10,
                                            2026. Mr.&nbsp;Sandoval&nbsp;brings more than 15 years of experience leading legal and compliance
                                            functions across the life sciences sector, with a particular focus on late-stage development,
                                            regulatory approval and first-product commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B><I><U>Fourth Quarter
and Full Year 2025 Financial Results</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">As
                                            of&nbsp;December&nbsp;31, 2025, Milestone had cash, cash equivalents, and short-term investments
                                            of&nbsp;$106.0 million, compared to&nbsp;$69.7 million&nbsp;on&nbsp;December&nbsp;31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There
                                            was $1.5 million of revenue recorded for the fourth quarter or full year ended&nbsp;December&nbsp;31,
                                            2025. The current year revenue was the result of a milestone pursuant to the Company&rsquo;s
                                            License and Collaboration Agreement with Corxel Pharmaceuticals due upon the successful NDA
                                            approval by the FDA in the U.S. of CARDAMYST for the treatment of PSVT.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research
                                            and development expense for the fourth quarter of 2025 was&nbsp;$5.5 million, compared with&nbsp;$3.9
                                            million&nbsp;for the prior year period. For the full year ended&nbsp;December&nbsp;31, 2025,
                                            research and development expense was&nbsp;$18.1 million, compared with&nbsp;$14.4 million&nbsp;for
                                            the prior year. The increase was primarily due to higher consulting and outside service costs,
                                            which were partially offset by lower personnel-related costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General
                                            and administrative expense for the fourth quarter of 2025 was&nbsp;$5.1 million, compared
                                            with&nbsp;$4.0 million&nbsp;for the prior year period. For the full year ended&nbsp;December&nbsp;31,
                                            2025, general and administrative expense was&nbsp;$17.3 million, compared with&nbsp;$16.7
                                            million&nbsp;for the prior year. This increase was driven primarily by an increase in outside
                                            service costs and higher personnel costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Commercial
                                            expense for the fourth quarter of 2025 was&nbsp;$8.2 million, compared with&nbsp;$4.4 million&nbsp;for
                                            the prior year period. For the full year ended&nbsp;December&nbsp;31, 2025, commercial expense
                                            was&nbsp;$28.3 million, compared with&nbsp;$11.0 million&nbsp;for the prior year. This increase
                                            is primarily a result of additional personnel costs, professional costs and other operational
                                            expenses related to preparation for the launch of CARDAMYST.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For
                                            the fourth quarter of 2025, net loss was&nbsp;$17.4 million or&nbsp;$0.16 per share, compared
                                            to&nbsp;a net loss of&nbsp;$12.4&nbsp;million&nbsp;or&nbsp;$0.19&nbsp;per share for the prior
                                            year period. For the full year ended&nbsp;December&nbsp;31, 2025, Milestone's net loss was&nbsp;$63.1
                                            million or&nbsp;$0.75&nbsp;per share, compared to&nbsp;a net loss of&nbsp;$41.5&nbsp;million&nbsp;or&nbsp;$0.67&nbsp;per
                                            share for the prior year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For further details
on the Company&rsquo;s financials, refer to the Annual Report on Form&nbsp;10-K for the year ended&nbsp;December&nbsp;31, 2025, filed
with the&nbsp;SEC&nbsp;on&nbsp;March&nbsp;20, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B><I><U>Conference
Call and Webcast Details</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left">Conference Dial-in:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">1-877-407-0792</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">International Dial-in:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">1-201-689-8263</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Conference ID:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">13759195</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Webcast link:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">click <U>here</U></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Call me&trade;:
Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me&trade; link for instant telephone
access to the event. The <U>Call me&trade; link</U> will be made active 15 minutes prior to scheduled start time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A replay of the audio webcast of the call will
be available <FONT STYLE="background-color: white">under the &ldquo;</FONT>Investors and Media&rdquo; section of Milestone's corporate
website, <U>www.milestonepharma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About CARDAMYST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B></B>CARDAMYST&trade;
(etripamil) nasal spray is approved by the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) for the conversion of acute symptomatic
episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray
designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The
product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management.
This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is
well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT.
Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute
atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit&nbsp;<U>CARDAMYST.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CARDAMYST is indicated
for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>IMPORTANT SAFETY
INFORMATION FOR CARDAMYST (etripamil)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>What is CARDAMYST?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CARDAMYST is a prescription
medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal
supraventricular tachycardia (PSVT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">It is not known if CARDAMYST
is safe and effective in children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Do not use CARDAMYST
if you:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">are
                                            allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete
                                            list of ingredients in CARDAMYST.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            limitations in activities due to heart failure (moderate to severe heart failure).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm
                                            pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            sick sinus syndrome without a permanent pacemaker.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            second degree or higher atrioventricular (AV) block.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Before using CARDAMYST,
tell your healthcare provider about all of your medical conditions, including if you:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            a history of fainting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">have
                                            low blood pressure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">are
                                            pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">are
                                            breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast
                                            milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this
                                            time, pump and throw away your breast milk. Talk to your healthcare provider about the best
                                            way to feed your baby after using CARDAMYST.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Tell your healthcare
provider about all the medicines you take</B>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>What are the possible
side effects of CARDAMYST?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>CARDAMYST may cause
serious side effects, including:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Fainting
                                            due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart.</B>
                                            CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting
                                            and certain heart problems, or people with a history of fainting during an episode of PSVT.
                                            Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or
                                            lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting
                                            occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>The most common side
effects of CARDAMYST include:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;nasal
    discomfort</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;nasal
    congestion</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;runny
    nose</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 67%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;throat
    irritation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;nosebleed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These are not all of
the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please see the full&nbsp;Prescribing Information <U>https://milestonepharma.com/etripamilprescribinginformation.pdf</U>
for CARDAMYST.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About&nbsp;Milestone Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>Milestone
Pharmaceuticals Inc.&nbsp;(Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular
medicines to benefit people living with certain heart conditions.&nbsp;Milestone&rsquo;s lead product is CARDAMYST&trade; (etripamil)
nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular
tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated
with AFib-RVR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note on Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such
as &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;demonstrate,&rdquo; &ldquo;designed,&rdquo; &ldquo;develop,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;pending,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;progress,&rdquo; &ldquo;will&rdquo;, &ldquo;intend&rdquo; and similar expressions (as well as other words or expressions referencing
future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are
based on Milestone&rsquo;s expectations and assumptions as of the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements
contained in this press release include statements regarding: Milestone&rsquo;s expectations regarding the promotional launch and commercialization
of CARDAMYST; expectations in regards to etripamil&rsquo;s efficacy; Milestone&rsquo;s ability to scale its operations, build the infrastructure
to support long-term growth, and drive value creation for shareholders; Milestone&rsquo;s expectations related to the reporting of prescription
data and insurance coverage for CARDAMYST; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including
the FDA and EMA; Milestone&rsquo;s plans to commence and timing of a Phase 3 study in AFib-RVR; Milestone&rsquo;s anticipated cash runway;
and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those
in the forward-looking statements include, but are not limited to, whether Milestone&rsquo;s future interactions with the EMA will have
satisfactory outcomes; whether and when, if at all, Milestone&rsquo;s MMA for etripamil will be approved by the EMA; uncertainties related
to the timing of initiation, enrollment, completion, evaluation and results of Milestone&rsquo;s clinical trials; risks and uncertainty
related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the
safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including
deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in&nbsp;Ukraine&nbsp;and
ongoing disputes in&nbsp;the Middle East&nbsp;and overall fluctuations in the financial markets in&nbsp;the United States&nbsp;and abroad,
risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone&rsquo;s capital resources and
its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone&rsquo;s filings
with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC), including in its annual report on Form&nbsp;10-K for the year ended&nbsp;December&nbsp;31,
2025 under the caption &ldquo;Risk Factors,&rdquo; as such discussions may be updated from time to time by subsequent filings Milestone
may make with the&nbsp;SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as required by law, Milestone assumes
no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information
becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP>2025 unaudited pro forma cash, cash
equivalents, and short-term investments was prepared by adding $94 million from RTW Royalty Purchase Agreement and subsequent financing
activities to audited cash, cash equivalents, and short-term investments as of December&nbsp;31, 2025, without further adjustment, as
if the payment had been made on December&nbsp;31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations<BR>
Kevin Gardner,&nbsp;<U>kgardner@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media Relations<BR>
Rebecca Novak,&nbsp;<U>rnovak@milestonepharma.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Milestone Pharmaceuticals
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Balance
Sheets&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(in thousands of US dollars, except share
data)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2025</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">73,046</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">25,314</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term investments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,914</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44,381</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">License receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,546</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development tax credits receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">316</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,805</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,840</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Inventory, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">648</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other receivables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,646</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,490</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,921</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,926</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease right-of-use assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,129</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,376</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">511</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">197</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">113,561</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">75,499</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities, and Shareholders' Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,289</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">647</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">571</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,979</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,126</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liabilities, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">874</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Senior secured convertible notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">57,191</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,352</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other long-term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">71,792</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">62,352</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Shareholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Common shares, no par value, unlimited shares authorized, 106,236,344 shares issued and outstanding as of December&nbsp;31, 2025, 53,353,984 shares issued and outstanding as of December&nbsp;31, 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">352,619</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">288,048</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Pre-funded warrants - 16,412,925 issued and outstanding as of December&nbsp;31, 2025 and 12,910,590 as of December&nbsp;31, 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,649</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,076</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,568</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(430,603</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(367,545</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total shareholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,769</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,147</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">113,561</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">75,499</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Milestone Pharmaceuticals Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Loss</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(in thousands of US dollars, except share
and per share data)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2025</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: bold 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,546</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development, net of tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,108</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,357</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,742</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Commercial</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,304</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,003</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(62,140</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(42,102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,164</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,838</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,581</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss and comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(63,058</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(41,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of shares and pre-funded warrants outstanding, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">83,882,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">62,210,702</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mist-20260320.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaCB6bOdzZR+uYkxtmB/bXmqfyImmjwuFiWEfWKmsfsO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:mist="http://milestonepharma.com/20260320" elementFormDefault="qualified" targetNamespace="http://milestonepharma.com/20260320">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://milestonepharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mist-20260320_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mist-20260320_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mist-20260320_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mist-20260320_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mist-20260320.xsd#Cover" roleURI="http://milestonepharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://milestonepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm269403d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm269403d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 28# 2(  A$! Q$!_\0
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M3BURNZ:33332::.>VO;^OTL.) Z_R)_.CM_G_#^E?R;_ /!7[_@MU\7O@O\
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M=-'VE+;Y?BN;/(,P\1?\)3_Q<)HA)G?]L+:?N_X]";?R\>)_\%$S\2_^%F?
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M,^.O_JO/%]?J-_P:ZG_BE?VQC@8&N?!TY[C&G?$+ZGMGZCC%?ES_ ,$*,_\
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M\4ZCXILOA=X1\9>"_%US?^&=>\-QV^NMXL$R162Z]86$M_;216\DBW5O&\.
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MQ)X/UBTUC3A=PK&]SIUVUJYDT[5;,31+?:5J$5KJ5C)(L=Y:P2?+7X->)_\
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MN+L6B>+]?^%^K1^&%#MLCNICI-SJOB&VLW)7=-/H$;0HQDN$AC5V7]E_ 7Q
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M6M>*H'CA-K_PC\ZA1'^N'Q@_9O\ V:?A1X-\ >#;V]FU_P 4^%[7Q[J7PI\
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MU&E&O*O3G2CRJ=&4DJD59*ZYHV>EM4FNC2:1[=_P2R^.7_!.']J.V\9_%/\
M99_9J^%_P!^*GPYGOM$\6Z/;?#'P+X5\>:'X/UZ[ODT#7%\2>%M+AL[C0_%N
MG:2[ZA::?J<QTK4K'4-)OS<6]O8ZGJGP]\>OVR?^""O[?7B+QGIW[1L=UX/\
M:^$=6U3POHGQ?OO!GB_POXD\5:;I$KV-IXB\+>.OA5'XF7Q!X8?:UQX=TSXD
MPQR+;R></#%LLIS^]O[/'[)?[/7[*7PUE^$WP+^&6A^"_!E^)&UZ!!=:KJOB
MJ[N+8V=S?^+->UB:_P!8\17D]LSP;]3O9X;:U?[%8PVEBD=LGY5?%K_@W8_X
M)[?$;7)=;\*V_P 7_@L;J666XT/X<^.K6]\.O-*[S320V'Q%T#QU?6 9W(AM
M--U.TTVVC58;2PBA5(T^:RC/.!)<3YWF6,S3Q%R/#2G0CPQF.7YFL=FV!H0;
M^LTLPK5L3*K7I5I*/U;#5)XFC0I5)K$>VK?O'E3KX3VU6<ZF+I*T51G&;E.*
M5[\S<[M/[,9726FKW_EI_8"U:[^%/_!5SX(Z/^RQXY\1^._!<O[2=CX!T+Q3
M;Z;J&AWWQ!^!NK^*3I7B.]\1:#/!:RQV%Y\//MNMZM;ZC80Q:9+8+K*VEC<:
M;;FV_4O_ (.A]*OXOC%^RAK4EM(FEW_PU^(FEVEX5;R)K_2?%&AW=_;+)C:9
M;:VUK3)9%#95;N(D ,*_?+]C#_@D9^QO^PWXJC^(WPL\->*_%/Q3M]-O]*L_
MB/\ $OQ&-?\ $&E6.K0/;:I!HFGZ5IV@>%M'EOK1Y;&?4+'PY'J[:=-<V!U(
MV=W>0W'O/[9'[#/[/?[>/P_T?P#\??#VKWMMX9U:XUSPEXB\+ZS-X?\ %GA3
M5+NU^P7T^DZCY%U:2V^H6BQQ7^FZMINIZ5>-;V=S+8M>6%C<6_U^8>+7#]7Q
M,X7XIP^$S.ME.19+6R7'8_$8;#T\WS&6)HUZ<L=/"4JT:<Y8>52#C3>(@ZBG
MB%1>'I^PI1VGF.'>-H5H\[A3IRA*;C[\U*ZYN5:65UHYIN[M962_(_\ 83_X
M+/\ [!WP^_9A_8Y^ ?B#Q]XN'Q3TGP%\'_@SX@\/VOP]\3?8_#?B:VM-)\&W
M&I:IXDO[33_#,GAV"]5-1GU#2M7U*YBTI_-%B]VDMDGXG?MN^!OB]_P28_X*
MM6_[2/A+2Y[SP?XG^)GB#XV_#759(6&C^+/"?CJZU!/BG\-;B]EMY;>UU.PM
MO$WB#PE>HADOM/TK5= \10I$=0LBO]!?PF_X-X/^"??PP\4Z7XMU;_A=/Q5N
M-%U"VU2QT7X@^/\ 3H- 6\LKF.ZL9;BT\ ^%? ^H7J6\T4;/:W>IS6-X$:*[
MM9[>1X6_5?\ :0_98^ W[7/P]/PO_:#^'>E?$+PC#J,>LZ=;WEQJ>EZGH>MQ
M6EU90ZSH&O:)>Z9K6C:G':7UU;&XL+^$3V\\UK=QSVLLD#^;A^.N!.&>*,7C
M.'L+Q!F_#_%.%S;"<:83.*6&ISK0S'&5<50EE-)5I:85XK$J=/$5(>WI2C!5
M(58PJQF.-PE"O)T?:5*5>-2.)C42NU.4I+D6NL;R5G+5/5II,_)'Q=_P<5_L
M!Z9\(KGQKX1U#XD>)OB9+HCW&D_!RX\ ZWH^M0:_+;.;73=?\57,)\"6NFV]
MZ8TU74M%\3:Y.EF))M.LM1N EJ_X6_\ !#?X!_$;]K+_ (*'7W[5GC'1YK_P
ME\*_$?C+XO\ CSQ3):RVVC:A\6?&XUF;PWH>GR!3%)J_]NZ[=^,#9Q.5L=.T
M+S+MXC=Z?'=_MY9?\&VW_!/ZT\4+K5QXC_:)U/1Q=/=#P;>?$'PM'H;Q[R_]
MG27^G?#^R\4M9(I$2F/Q!%J.Q0SZB[[G;]IO@9\ O@[^S3\/=.^%OP+^'^A?
M#CP)I=Q<7L.A:%%.4N-1NEBCO-5U34+Z>[U76=8NX[:WCN]6U>]O=1N$@@CG
MN'CAB"98GC+P_P"%>'.(LJ\.\-Q#7S/BK#?4,;F6?*E3CEV7SC5A4P^%5.M4
MG5J1IUZU.D^6-ZD_;XBK4]G"DY>*P="C6IX15)5*\>64JFCA!]$KZM)M+1;\
MS;5F_P"$7]O'_E.=XL_[.O\ @+Q_P'X7_7_/K7]^'C4?\45XMQT_X1?Q!W'_
M $"K[GKTZGK7YL?$_P#X(Z_L;?%[]IRY_:U\6V/Q+7XJ7OC?PC\0;R+2_'+V
M7A:?Q%X,CT1-+D;2&TF:YCM)O^$?L7O[6'4HQ*[7'DO;+*$C_46^LK6_L+S3
M;N(RV=_:7-E=1AGC,EM=0O!,@=,.K/'*ZAD8,N<AP0#7SO'O&.4<2X3P^HY;
M'&J?#&187+LR6)PZH1>(H5,OE-81K$5O;4N7"5%&<HT&VXW@N9\N6+Q5*M#"
MJ'-^YIQC/F5K-<E[>\[KW79Z771['\"__!NV<?\ !2#0#W_X4]\5,>Q^PZ7C
MITP2/J,^]>'_ +9/P+\1_P#!.+_@I#?:K\3/AEX9^)7POF^*VH?%SP9H'BS0
M;/Q'X$^*OP<\3>)M0O+GPY<6VO:=-I<^L:;I%[>^%=86>SE?P_XILHM7LTEM
M?['OKO\ LD_9,_X)#_L<_L9?%M?C;\%M)^(=OXWB\/:UX:M'\4>.;K7]+L]-
M\0-;#4!#8-86ADN3%:);PS74MQY44DK;'G*3)]/?M4_L8?LX_MI^"M-\#?M$
M_#NT\;:9H5Y<ZEX9U*'4=5T#Q+X5U*\AC@N[OP_XBT*]T_5+(7<<%L+^P>>?
M2=3^R6@U33KU+6%4_0<3XSY-#C[%9OA\'F.*X7SGAC+N'\YH3HQPF9PGA%BF
ML3@XPQDDY4)XNHDEBZ,JM&3=.="M2HS?6\SI?674C&<J%2C"E437+/W4[2BE
M*_NN7=-K;EDC\$=3_P""@G_!O19?#P>,++]F?X3ZOXI;2Q?)\*K7]D#0K?QD
M+\Q!_P"Q9]8O_"EI\.HKJ*5EBEO8O&MQII :6WNK@+M/Z*?\$YOVD/\ @GC\
M0_@7K'[2W[/OP4^&W[,MQ/KO_"M/B5H6A?#KPUX?\76/B*QM%\20>')KOP-H
MJ77B_2)M(/\ PE&G76GV\D TRWO[_4+'39]'U6*Q^=]%_P"#;+_@G]IGB)-9
MU#Q+^T5XCTJ.Z%Q_PB6K?$'PK;:+-%G)L;F]T'X>Z-XE-K_"KVNO6EZ$'S7C
MR9D/ZM:3^Q/^S9X6^"ME^S]X#^&^E?#WX8:=>ZEJ5IHGA(&W=M2UO0-3\*:]
MJ.JW.JC5F\2WNO\ A;6M6\/ZW<^*EUR74M-OY([EGF@M)K?XOBC./#NKEU/
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M.PGN-&T7:FC:1IFBZ6$TW2;2RBCA:9HA-<WUW']KN9R?+BBYKPQ^REHOAGX
M>/O@)%XQU2[T_P >2>-9+GQ'+I=K'>Z<?&=P+B86]@EVT$PL2 J%YT-P "YC
M(J/K?"5-3PRPV&KQIXGA.F\8\%C(U,12PWUB/%&)H.6)4Z5+%\N%G3A6IQKS
M7M71A0E-PCU_V)XU8JI1S6>:9KE]3$99XQXN&1PS[)*F%RW&9K++:OA-E68P
MI98\/C,7DRGFU#$8C!8J> H2^J0QM?'T\/&M5Y/QC^TC\0M2\1_#;X3_  A\
M+^$M3^*OC3X76'Q:\0ZAXUU#4M,\"^#_  G=+%;^=)_9L=UK&K7MYJWF6%K9
M6H)MXS;SW+RB=VA].\5?&GQ#\(/@-JGQ,^-&C>&M-\4Z/:R0?V!X+UC4O$&E
M:[K=W>+I_AS3](N;[2].OUFUZZFM]UL]K,-,1Y'FNY(()9DPOB)^RY;>*+3P
M%K?@?X@:U\+OBW\./"]EX.\/?%'1-)LM4N;OPU!;+;W.A>)?#E[=06'B#1YY
M!)?VME<W<3:;J4CW5M<%7FAFS_%?[)D'Q%\'_##P/\3/BSX^\<Z)X%UW4/%'
MB&34'MM+U?QSK]Q!=+IL]SK&A2:=J&B66@W=]=W.EVMG/=72J\$,^HS&T@F7
M)2X3JK)^>=##X6GBYSSBG# YA/.*L:.)S"O-X?%_6%@OJ&,PW]GX/"8=0AB,
M--U76G&4)XFKT2P_C1A*G&LJ-''YEG&)R:C1X)Q-?B#AO#\$82IC,LX=R^A#
M,<G>7O/?]8\DS3_6/.LYS25:OEF:4HX6. HU*5?#Y7@\[6_VH]33]DFY_:%T
M'P]I_P#PD.GZ/:?VKX8U47BV>D^*K3Q+;^%?%.AWD<<MOJ"KI6K?;K>+?)%-
M*L=O,WR2%:ZW]J/XX^*_@C\)[/X@>%?"MKXBEG\0Z+H^M7^HIJD^B>#-&U07
M O/%FN6FBV\^JWFEZ;/%#9RV]CLF::]@?<^/)FXH?L7Z)9?#SXT?"C1/B+XH
ML? /Q;N])U:STG4H#XDO_!>O6UY8ZAKVJV6O:SJEQJ^MMXHOM/@O-0M]5N2L
M-SYDT4C233-)VB? KXIM\--5\%WG[2WC6Z\3W&MVNJ:-X\'@SP3;RZ5IUM:1
MVQ\,WOAJ*S_LC6]"NI5ENKN&=[:ZFDD2+[4MNCQ3"7"=/%X>O1JX:OA:6?SK
MU,'C:.:TIU\EQE#!SI8:M5P\:KBLKKRQE*MRSE5J*E3J4_K5.K* I?\ $:<1
MDV9Y=CL'FN S?&>&U# X;/,AQ_!^,I9;Q]DN89W1Q>9X+"9E4P4*KXKR^&28
MS!.K1HX3#/%8C#8F.4XC!PK2]#^ _CS4_B7\+O#7C35+[P1JUQK27TBZE\/M
M1U#4/"]Y!;:C>V<4MH^L:?I^I6=VJVZQ:GI=Y;F?2]16ZL9)I7MW=O91R!_^
MO^7%>)? 7X+Z1\!_A[9>!M,U>\U^8:EJ^NZUK=S9VFE#5-=UZ]EOM3N[31M.
M(TW0[ RR+%8Z3IZ_9K*WAB0/+*))I/:PX]S]<?XU\OF?U/\ M''/+YN>!^M5
M_JDW1^KN6'<W[)^QYI>R]W:-]E%VAS.G#]@X1CGL>&.'UQ/1C0XB63X!9W1C
MCEF2IYFJ$5BX_7U3I+%/VBO*JH6<Y5(<];V4<17?13-X]#^G^-&\>A_3_&N$
M^C'T4S>/0_I_C10!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 20, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 20,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MILESTONE
PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001408443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1111
    Dr. Frederik-Philips Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Montr&#233;al<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H4M
    2X6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">336-0444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MIST<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm269403d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://milestonepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mist-20260320.xsd</File>
    <File>mist-20260320_lab.xml</File>
    <File>mist-20260320_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm269403d1_8k.htm">tm269403d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm269403d1_8k.htm": {
   "nsprefix": "mist",
   "nsuri": "http://milestonepharma.com/20260320",
   "dts": {
    "schema": {
     "local": [
      "mist-20260320.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mist-20260320_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mist-20260320_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm269403d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://milestonepharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm269403d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm269403d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://milestonepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-26-032427-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-032427-xbrl.zip
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MIB((%$!;.@<'(5)*QQ#<<2(A)*(CBI< 96(A?OOP8)WMN\2NH.@WK." E4%
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M:]O04_BF"% <&A_4-PJ!,52$Z:)SI.O6'G!OJRV^<;_<&UGMD?\!4$L#!!0
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M*)L=&%-:Q=T"QVR9AL4M=-?!#JE[)JQN*"#M6FFW%,1PW\/3%LR?0P=4YE3
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M2: _$@2'N"/\Q!V!="IE.8 F)Z ]V#F2C-1#T"=@^G8;@10K3_B(MG!P,W1
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MB"%\Q)19@MX!X/#:X?7=)7WJ)D2%'3\DC\:_N NJ^5#;3K5F.2,-7@<;7_[
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M1W%4+L]"'D#+!-V1*1,3F)LF@N-CUG+="-.B$U17Z&RP5 9"O8*J%6',I>\
MMPUBF3$34(*HCR;M/P)5*NZ -4K[QQ ;>I)!Y8LC\VV"UD!#R^QQMRLH&H=_
M6RIJG-,FUZ(,@(PY$6D.(>/^.OD ; ]0'$-:35^=W\B*8!$1Q>QF6@H(V9!9
M7J#2$,A_+H/OM*S><."!MB_E&L!M",)Y( PM<66\'(X6+Z+8<, [8B0,Z2L^
MF&=9&9ZI,3 1P(7&NSY<[_@X'^J,LQ*9\.!CU KH'>#Z;T HG71P3VF .A<E
M$<&8% $66#B,PV[YEM$7I*=+[J<L9: QYA'AT),IQFYW>PXE$22)-GZ 3#9(
MV 3<#J:Z)%&9?#&3&Z1-WCSTO9DVAO0 &DGJ1SIG")5]!S,VUT&YTVK4Z7.1
M4DO&S0UB3)F:C!9Q=/;%;OMP[M+$HB^N,5K*_DKE*UTC3]]NP:6EZ[^N=V)
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M-$'4^>.DUG2X[6"SU>T^Z"MD9E)/R7M,_LY<L5-@SII@S@_/Z71*5]R_L]W
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MUG]GV:B)ZQ\$0!+ZMW@09[629Q3BUO/4H)<YDEXZ>CH>T-Z<WX#VK:.? C"
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M5?#A\^7)SR/\Y<_;B_.C_P]02P$"% ,4    "  C.W1<H0O:DBT#  #W"P
M$0              @ $     ;6ES="TR,#(V,#,R,"YX<V102P$"% ,4
M"  C.W1<8=)W_/T*  !_A@  %0              @ %< P  ;6ES="TR,#(V
M,#,R,%]L86(N>&UL4$L! A0#%     @ (SMT7&T0!!9A!P  XE<  !4
M         ( !C X  &UI<W0M,C R-C S,C!?<')E+GAM;%!+ 0(4 Q0    (
M ",[=%R7"$>CA!,  -IG   1              "  2 6  !T;3(V.30P,V0Q
M7SAK+FAT;5!+ 0(4 Q0    ( ",[=%PXV&(_TRL  -"+ 0 5
M  "  =,I  !T;3(V.30P,V0Q7V5X.3DM,2YH=&U02P4&      4 !0!' 0
&V54

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm269403d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mist-20260320.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001408443</identifier>
        </entity>
        <period>
            <startDate>2026-03-20</startDate>
            <endDate>2026-03-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-20" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-20" id="Fact000004">0001408443</dei:EntityCentralIndexKey>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-20" id="xdx2ixbrl0012">A8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-20" id="xdx2ixbrl0014">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-20" id="xdx2ixbrl0018">QC</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="AsOf2026-03-20" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-20" id="Fact000010">2026-03-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-20" id="Fact000011">MILESTONE PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="AsOf2026-03-20" id="Fact000013">001-38899</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-20" id="Fact000015">1111     Dr. Frederik-Philips Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-03-20" id="Fact000016">Suite     420</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-20" id="Fact000017">Montr&#xe9;al</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2026-03-20" id="Fact000019">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-20" id="Fact000020">H4M     2X6</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-20" id="Fact000021">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-20" id="Fact000022">336-0444</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-20" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-20" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-20" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-20" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-20" id="Fact000027">Common     Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-20" id="Fact000028">MIST</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-20" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-20" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
